CUREVAC NV (5CV.DE) Stock Fundamental Analysis
Europe - FRA:5CV - NL0015436031 - Common Stock
4.572 EUR
+0.01 (+0.31%)
Overall 5CV gets a fundamental rating of 6 out of 10. We evaluated 5CV against 75 industry peers in the Biotechnology industry. While 5CV has a great health rating, its profitability is only average at the moment. 5CV is not valued too expensively and it also shows a decent growth rate.
1. Profitability
1.1 Basic Checks
5CV had positive earnings in the past year.
5CV had a positive operating cash flow in the past year.
5CV had negative earnings in 4 of the past 5 years.
In multiple years 5CV reported negative operating cash flow during the last 5 years.
1.2 Ratios
The Return On Assets of 5CV (28.11%) is better than 93.33% of its industry peers.
The Return On Equity of 5CV (33.02%) is better than 93.33% of its industry peers.
5CV has a better Return On Invested Capital (28.35%) than 98.67% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 28.11% | ||
| ROE | 33.02% | ||
| ROIC | 28.35% |
ROA(3y)-13.91%
ROA(5y)-17.17%
ROE(3y)-24.58%
ROE(5y)-30.34%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
The Profit Margin of 5CV (37.93%) is better than 92.00% of its industry peers.
5CV has a Operating Margin of 40.58%. This is amongst the best in the industry. 5CV outperforms 96.00% of its industry peers.
With an excellent Gross Margin value of 94.81%, 5CV belongs to the best of the industry, outperforming 90.67% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 40.58% | ||
| PM (TTM) | 37.93% | ||
| GM | 94.81% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
2. Health
2.1 Basic Checks
5CV has a Return on Invested Capital (ROIC), which is well above the Cost of Capital (WACC), which means it is creating value.
The number of shares outstanding for 5CV remains at a similar level compared to 1 year ago.
Compared to 5 years ago, 5CV has more shares outstanding
5CV has a better debt/assets ratio than last year.
2.2 Solvency
5CV has an Altman-Z score of 9.51. This indicates that 5CV is financially healthy and has little risk of bankruptcy at the moment.
The Altman-Z score of 5CV (9.51) is better than 86.67% of its industry peers.
The Debt to FCF ratio of 5CV is 0.18, which is an excellent value as it means it would take 5CV, only 0.18 years of fcf income to pay off all of its debts.
5CV's Debt to FCF ratio of 0.18 is amongst the best of the industry. 5CV outperforms 93.33% of its industry peers.
A Debt/Equity ratio of 0.05 indicates that 5CV is not too dependend on debt financing.
With a decent Debt to Equity ratio value of 0.05, 5CV is doing good in the industry, outperforming 68.00% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.05 | ||
| Debt/FCF | 0.18 | ||
| Altman-Z | 9.51 |
ROIC/WACC3.92
WACC7.24%
2.3 Liquidity
A Current Ratio of 6.17 indicates that 5CV has no problem at all paying its short term obligations.
5CV has a Current ratio of 6.17. This is amongst the best in the industry. 5CV outperforms 85.33% of its industry peers.
A Quick Ratio of 6.16 indicates that 5CV has no problem at all paying its short term obligations.
Looking at the Quick ratio, with a value of 6.16, 5CV belongs to the top of the industry, outperforming 85.33% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 6.17 | ||
| Quick Ratio | 6.16 |
3. Growth
3.1 Past
5CV shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 170.16%, which is quite impressive.
5CV shows a strong growth in Revenue. In the last year, the Revenue has grown by 675.15%.
Measured over the past years, 5CV shows a very strong growth in Revenue. The Revenue has been growing by 98.42% on average per year.
EPS 1Y (TTM)170.16%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%18.75%
Revenue 1Y (TTM)675.15%
Revenue growth 3Y73.2%
Revenue growth 5Y98.42%
Sales Q2Q%-91.38%
3.2 Future
The Earnings Per Share is expected to decrease by -22.50% on average over the next years. This is quite bad
The Revenue is expected to decrease by -10.88% on average over the next years. This is quite bad
EPS Next Y-170.56%
EPS Next 2Y-63.78%
EPS Next 3Y-28.72%
EPS Next 5Y-22.5%
Revenue Next Year-86.75%
Revenue Next 2Y-59.56%
Revenue Next 3Y-30.85%
Revenue Next 5Y-10.88%
3.3 Evolution
When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is decreasing.
4. Valuation
4.1 Price/Earnings Ratio
With a Price/Earnings ratio of 5.26, the valuation of 5CV can be described as very cheap.
Compared to the rest of the industry, the Price/Earnings ratio of 5CV indicates a rather cheap valuation: 5CV is cheaper than 96.00% of the companies listed in the same industry.
5CV's Price/Earnings ratio indicates a rather cheap valuation when compared to the S&P500 average which is at 25.56.
The Forward Price/Earnings Ratio is negative for 5CV. No positive earnings are expected for the next year.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 5.26 | ||
| Fwd PE | N/A |
4.2 Price Multiples
Based on the Enterprise Value to EBITDA ratio, 5CV is valued cheaply inside the industry as 96.00% of the companies are valued more expensively.
Based on the Price/Free Cash Flow ratio, 5CV is valued cheaply inside the industry as 94.67% of the companies are valued more expensively.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 5.25 | ||
| EV/EBITDA | 2.96 |
4.3 Compensation for Growth
The decent profitability rating of 5CV may justify a higher PE ratio.
5CV's earnings are expected to decrease with -28.72% in the coming years. This may justify a cheaper valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-63.78%
EPS Next 3Y-28.72%
5. Dividend
5.1 Amount
5CV does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
FRA:5CV (11/17/2025, 7:00:00 PM)
4.572
+0.01 (+0.31%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)
Earnings (Next)
Inst Owners6.53%
Inst Owner ChangeN/A
Ins Owners0.12%
Ins Owner ChangeN/A
Market Cap1.03B
Revenue(TTM)510.51M
Net Income(TTM)193.64M
Analysts72.31
Price Target4.24 (-7.26%)
Short Float %N/A
Short RatioN/A
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-29.18%
Min EPS beat(2)-39.67%
Max EPS beat(2)-18.68%
EPS beat(4)2
Avg EPS beat(4)34.62%
Min EPS beat(4)-39.67%
Max EPS beat(4)161.44%
EPS beat(8)3
Avg EPS beat(8)-1.81%
EPS beat(12)5
Avg EPS beat(12)-8.17%
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)0
Avg Revenue beat(2)-91.68%
Min Revenue beat(2)-96.47%
Max Revenue beat(2)-86.88%
Revenue beat(4)2
Avg Revenue beat(4)75.38%
Min Revenue beat(4)-96.47%
Max Revenue beat(4)366.65%
Revenue beat(8)4
Avg Revenue beat(8)53.09%
Revenue beat(12)4
Avg Revenue beat(12)21.18%
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)1.18%
PT rev (3m)-0.18%
EPS NQ rev (1m)0%
EPS NQ rev (3m)-275%
EPS NY rev (1m)-7.12%
EPS NY rev (3m)-7.12%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)220.62%
Revenue NY rev (1m)0.35%
Revenue NY rev (3m)-13.75%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 5.26 | ||
| Fwd PE | N/A | ||
| P/S | 2.02 | ||
| P/FCF | 5.25 | ||
| P/OCF | 5.04 | ||
| P/B | 1.76 | ||
| P/tB | 1.83 | ||
| EV/EBITDA | 2.96 |
EPS(TTM)0.87
EY19.03%
EPS(NY)-0.5
Fwd EYN/A
FCF(TTM)0.87
FCFY19.05%
OCF(TTM)0.91
OCFY19.82%
SpS2.27
BVpS2.6
TBVpS2.49
PEG (NY)N/A
PEG (5Y)N/A
Graham Number7.14
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 28.11% | ||
| ROE | 33.02% | ||
| ROCE | 33.37% | ||
| ROIC | 28.35% | ||
| ROICexc | 78.22% | ||
| ROICexgc | 88.03% | ||
| OM | 40.58% | ||
| PM (TTM) | 37.93% | ||
| GM | 94.81% | ||
| FCFM | 38.42% |
ROA(3y)-13.91%
ROA(5y)-17.17%
ROE(3y)-24.58%
ROE(5y)-30.34%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score9
Asset Turnover0.74
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.05 | ||
| Debt/FCF | 0.18 | ||
| Debt/EBITDA | 0.14 | ||
| Cap/Depr | 44.58% | ||
| Cap/Sales | 1.55% | ||
| Interest Coverage | 91.31 | ||
| Cash Conversion | 90.71% | ||
| Profit Quality | 101.3% | ||
| Current Ratio | 6.17 | ||
| Quick Ratio | 6.16 | ||
| Altman-Z | 9.51 |
F-Score9
WACC7.24%
ROIC/WACC3.92
Cap/Depr(3y)242.45%
Cap/Depr(5y)397%
Cap/Sales(3y)81.47%
Cap/Sales(5y)93.1%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)170.16%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%18.75%
EPS Next Y-170.56%
EPS Next 2Y-63.78%
EPS Next 3Y-28.72%
EPS Next 5Y-22.5%
Revenue 1Y (TTM)675.15%
Revenue growth 3Y73.2%
Revenue growth 5Y98.42%
Sales Q2Q%-91.38%
Revenue Next Year-86.75%
Revenue Next 2Y-59.56%
Revenue Next 3Y-30.85%
Revenue Next 5Y-10.88%
EBIT growth 1Y171.44%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-152.22%
EBIT Next 3Y-32.99%
EBIT Next 5Y10.78%
FCF growth 1Y160.43%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y182.06%
OCF growth 3YN/A
OCF growth 5YN/A
CUREVAC NV / 5CV.DE FAQ
Can you provide the ChartMill fundamental rating for CUREVAC NV?
ChartMill assigns a fundamental rating of 6 / 10 to 5CV.DE.
Can you provide the valuation status for CUREVAC NV?
ChartMill assigns a valuation rating of 5 / 10 to CUREVAC NV (5CV.DE). This can be considered as Fairly Valued.
What is the profitability of 5CV stock?
CUREVAC NV (5CV.DE) has a profitability rating of 6 / 10.
What is the financial health of CUREVAC NV (5CV.DE) stock?
The financial health rating of CUREVAC NV (5CV.DE) is 9 / 10.